Inclusion Criteria:  Either gender,18-65 years of age Left ventricular ejection fraction <40% as assessed by 2D echocardiography NYHA class II-III CHF patients currently optimized on standard treatment for at least 1 month before enrolment and on an OPD basis treatment Ready to give written informed consent Willing to comply with the study protocol  Exclusion Criteria:  Known hypersensitivity to statins NYHA class IV patient Serum creatinine >3 mg/dl Significant liver disease: SGOT/SGPT >3 times the upper limit of normal (ULN) or >2.5 times the ULN in symptomatic patients Patient on an enzyme inducer or inhibitor currently Any malignancy or patient on chemotherapeutic agents Pregnant or lactating females Patients who have participated in another trial within the past 3 months Patient with uncontrolled diabetes mellitus (HbA1c >7 g%)/ uncontrolled hypertension (BP >140/90 mmHg despite in ≥3 antihypertensive drugs) Patient with HIV/ HBV / HCV infection